Logo image of HCAT

HEALTH CATALYST INC (HCAT) Stock Fundamental Analysis

USA - NASDAQ:HCAT - US42225T1079 - Common Stock

3.13 USD
-0.11 (-3.4%)
Last: 9/12/2025, 8:00:01 PM
3.13 USD
0 (0%)
After Hours: 9/12/2025, 8:00:01 PM
Fundamental Rating

2

Overall HCAT gets a fundamental rating of 2 out of 10. We evaluated HCAT against 35 industry peers in the Health Care Technology industry. HCAT may be in some trouble as it scores bad on both profitability and health. HCAT has a valuation in line with the averages, but on the other hand it scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year HCAT was profitable.
In the past year HCAT has reported a negative cash flow from operations.
HCAT had negative earnings in each of the past 5 years.
HCAT had negative operating cash flow in 4 of the past 5 years.
HCAT Yearly Net Income VS EBIT VS OCF VS FCFHCAT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M -200M

1.2 Ratios

HCAT has a Return On Assets (-16.25%) which is comparable to the rest of the industry.
HCAT has a Return On Equity of -28.81%. This is comparable to the rest of the industry: HCAT outperforms 54.29% of its industry peers.
Industry RankSector Rank
ROA -16.25%
ROE -28.81%
ROIC N/A
ROA(3y)-14.4%
ROA(5y)-16.3%
ROE(3y)-27.85%
ROE(5y)-30.91%
ROIC(3y)N/A
ROIC(5y)N/A
HCAT Yearly ROA, ROE, ROICHCAT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

Looking at the Gross Margin, with a value of 46.00%, HCAT is doing worse than 60.00% of the companies in the same industry.
In the last couple of years the Gross Margin of HCAT has declined.
The Profit Margin and Operating Margin are not available for HCAT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 46%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.71%
GM growth 5Y-2.4%
HCAT Yearly Profit, Operating, Gross MarginsHCAT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

1

2. Health

2.1 Basic Checks

HCAT does not have a ROIC to compare to the WACC, probably because it is not profitable.
HCAT has more shares outstanding than it did 1 year ago.
The number of shares outstanding for HCAT has been increased compared to 5 years ago.
The debt/assets ratio for HCAT is higher compared to a year ago.
HCAT Yearly Shares OutstandingHCAT Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
HCAT Yearly Total Debt VS Total AssetsHCAT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

Based on the Altman-Z score of -1.93, we must say that HCAT is in the distress zone and has some risk of bankruptcy.
HCAT's Altman-Z score of -1.93 is on the low side compared to the rest of the industry. HCAT is outperformed by 68.57% of its industry peers.
A Debt/Equity ratio of 0.44 indicates that HCAT is not too dependend on debt financing.
HCAT has a Debt to Equity ratio of 0.44. This is in the lower half of the industry: HCAT underperforms 62.86% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.44
Debt/FCF N/A
Altman-Z -1.93
ROIC/WACCN/A
WACC8.09%
HCAT Yearly LT Debt VS Equity VS FCFHCAT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M 400M 500M

2.3 Liquidity

HCAT has a Current Ratio of 1.83. This is a normal value and indicates that HCAT is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of HCAT (1.83) is worse than 60.00% of its industry peers.
A Quick Ratio of 1.83 indicates that HCAT should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.83, HCAT is not doing good in the industry: 60.00% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.83
Quick Ratio 1.83
HCAT Yearly Current Assets VS Current LiabilitesHCAT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for HCAT have decreased strongly by -27.27% in the last year.
Looking at the last year, HCAT shows a small growth in Revenue. The Revenue has grown by 5.55% in the last year.
Measured over the past years, HCAT shows a quite strong growth in Revenue. The Revenue has been growing by 14.63% on average per year.
EPS 1Y (TTM)-27.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-66.67%
Revenue 1Y (TTM)5.55%
Revenue growth 3Y8.22%
Revenue growth 5Y14.63%
Sales Q2Q%6.35%

3.2 Future

The Earnings Per Share is expected to grow by 7.01% on average over the next years.
HCAT is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 1.17% yearly.
EPS Next Y-19.86%
EPS Next 2Y19.82%
EPS Next 3Y25.61%
EPS Next 5Y7.01%
Revenue Next Year3.51%
Revenue Next 2Y2.91%
Revenue Next 3Y1.83%
Revenue Next 5Y1.17%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
HCAT Yearly Revenue VS EstimatesHCAT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 100M 200M 300M
HCAT Yearly EPS VS EstimatesHCAT Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 0.5 -0.5 -1

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 19.56 indicates a rather expensive valuation of HCAT.
Compared to the rest of the industry, the Price/Earnings ratio of HCAT indicates a rather cheap valuation: HCAT is cheaper than 94.29% of the companies listed in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 27.30, HCAT is valued a bit cheaper.
Based on the Price/Forward Earnings ratio of 7.79, the valuation of HCAT can be described as very cheap.
Based on the Price/Forward Earnings ratio, HCAT is valued cheaply inside the industry as 100.00% of the companies are valued more expensively.
HCAT's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 22.73.
Industry RankSector Rank
PE 19.56
Fwd PE 7.79
HCAT Price Earnings VS Forward Price EarningsHCAT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HCAT Per share dataHCAT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3 4

4.3 Compensation for Growth

A more expensive valuation may be justified as HCAT's earnings are expected to grow with 25.61% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.82%
EPS Next 3Y25.61%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for HCAT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HEALTH CATALYST INC

NASDAQ:HCAT (9/12/2025, 8:00:01 PM)

After market: 3.13 0 (0%)

3.13

-0.11 (-3.4%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)11-04 2025-11-04/amc
Inst Owners80.75%
Inst Owner Change-0.36%
Ins Owners3.4%
Ins Owner Change2.97%
Market Cap220.26M
Analysts73.33
Price Target4.65 (48.56%)
Short Float %7.32%
Short Ratio6.38
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)202.94%
Min EPS beat(2)15.68%
Max EPS beat(2)390.2%
EPS beat(4)2
Avg EPS beat(4)82.29%
Min EPS beat(4)-46.95%
Max EPS beat(4)390.2%
EPS beat(8)6
Avg EPS beat(8)423.36%
EPS beat(12)10
Avg EPS beat(12)426.62%
EPS beat(16)14
Avg EPS beat(16)329.36%
Revenue beat(2)0
Avg Revenue beat(2)-1.74%
Min Revenue beat(2)-1.82%
Max Revenue beat(2)-1.66%
Revenue beat(4)0
Avg Revenue beat(4)-1.85%
Min Revenue beat(4)-2.04%
Max Revenue beat(4)-1.66%
Revenue beat(8)1
Avg Revenue beat(8)-1.34%
Revenue beat(12)3
Avg Revenue beat(12)-0.88%
Revenue beat(16)5
Avg Revenue beat(16)-0.65%
PT rev (1m)-34.92%
PT rev (3m)-43.05%
EPS NQ rev (1m)-20%
EPS NQ rev (3m)-28.53%
EPS NY rev (1m)-7.95%
EPS NY rev (3m)-25.22%
Revenue NQ rev (1m)-8.88%
Revenue NQ rev (3m)-8.41%
Revenue NY rev (1m)-5.08%
Revenue NY rev (3m)-5.09%
Valuation
Industry RankSector Rank
PE 19.56
Fwd PE 7.79
P/S 0.7
P/FCF N/A
P/OCF N/A
P/B 0.63
P/tB N/A
EV/EBITDA N/A
EPS(TTM)0.16
EY5.11%
EPS(NY)0.4
Fwd EY12.84%
FCF(TTM)-0.37
FCFYN/A
OCF(TTM)-0.09
OCFYN/A
SpS4.49
BVpS4.94
TBVpS-0.52
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -16.25%
ROE -28.81%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 46%
FCFM N/A
ROA(3y)-14.4%
ROA(5y)-16.3%
ROE(3y)-27.85%
ROE(5y)-30.91%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.71%
GM growth 5Y-2.4%
F-Score5
Asset Turnover0.51
Health
Industry RankSector Rank
Debt/Equity 0.44
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 44.35%
Cap/Sales 6.35%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.83
Quick Ratio 1.83
Altman-Z -1.93
F-Score5
WACC8.09%
ROIC/WACCN/A
Cap/Depr(3y)36.51%
Cap/Depr(5y)42.93%
Cap/Sales(3y)5.5%
Cap/Sales(5y)5.93%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-27.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-66.67%
EPS Next Y-19.86%
EPS Next 2Y19.82%
EPS Next 3Y25.61%
EPS Next 5Y7.01%
Revenue 1Y (TTM)5.55%
Revenue growth 3Y8.22%
Revenue growth 5Y14.63%
Sales Q2Q%6.35%
Revenue Next Year3.51%
Revenue Next 2Y2.91%
Revenue Next 3Y1.83%
Revenue Next 5Y1.17%
EBIT growth 1Y32.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year162.31%
EBIT Next 3Y44.05%
EBIT Next 5Y29.42%
FCF growth 1Y57.01%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y86.28%
OCF growth 3YN/A
OCF growth 5YN/A